ESC 365 - Estimating individual lifetime benefit and bleeding risk of adding rivaroxaban to aspirin for patients with stable cardiovascular disease: results from the COMPASS trial

ESC Premium Access

Estimating individual lifetime benefit and bleeding risk of adding rivaroxaban to aspirin for patients with stable cardiovascular disease: results from the COMPASS trial

Session: Young Investigator Award Session Thrombosis

Topic: Secondary Prevention

Speaker: Miss T. de Vries (Utrecht, NL)

Event: ESC Congress 2019

Congress Presentation

Add to my library

About the speaker

Miss Tamar de Vries

University Medical Center Utrecht, Utrecht (Netherlands (The))

0 follower

3 more presentations in this session

The prothrombotic transcriptome of reticulated platelets

Speaker: Doctor D. Bongiovanni (Augsburg, DE)

Sirtuin 5 regulates arterial thrombosis by modulating endothelial plasminogen activator inhibitor-1

Speaker: Doctor L. Liberale (Genova, IT)

Intravenous administration of IV-STATIN CARDIOSHIELD during myocardial infarction renders higher cardioprotection than oral atorvastatin given shortly after reperfusion: a translational CMR study

Speaker: Doctor G. Mendieta Badimon (Barcelona, ES)

Access the full session

Young Investigator Award Session Thrombosis

Speakers: Miss T. de Vries, Doctor D. Bongiovanni, Doctor L. Liberale, Doctor G. Mendieta Badimon

About the event

ESC Congress 2019

31 August - 4 September 2019

Sessions Presentations

Congress

ESC 365 is supported by

Explore sponsored resources

Explore sponsored resources